Panmure Gordon reiterated their buy rating on shares of Ekf Diagnostics Holding PLC (LON:EKF) in a research note issued to investors on Wednesday. Panmure Gordon currently has a GBX 21 ($0.26) target price on the stock.
Several other research firms also recently weighed in on EKF. FinnCap reaffirmed an under review rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, November 29th. N+1 Singer reaffirmed a corporate rating on shares of Ekf Diagnostics Holding PLC in a report on Monday, January 9th.
Ekf Diagnostics Holding PLC (LON:EKF) opened at 19.17675 on Wednesday. The stock’s market capitalization is GBX 82.23 million. Ekf Diagnostics Holding PLC has a 12-month low of GBX 9.48 and a 12-month high of GBX 19.75. The firm’s 50-day moving average is GBX 18.15 and its 200 day moving average is GBX 17.00.
var userip;Your IP Address: document.write(userip);
About Ekf Diagnostics Holding PLC
EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company’s point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases.
Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.